Recent FDA Approval of Advanced Treatment for Patients with Metastatic Non Small-Cell Lung Cancer (NSCLC) Demonstrates Importance of Participation in Clinical Trials
06 déc. 2022 15h41 HE | Florida Cancer Specialists & Research Institute
Ft. Myers, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- A clinical study conducted with participation by Florida Cancer Specialists & Research Institute, LLC (FCS) has led to FDA approval of a new...
Flow Cytometry in Oncology and Immunology Global Market Report 2022: Innovation in Flow Cytometry Leading to Use of Next-Generation Flow Cytometers
29 nov. 2022 04h03 HE | Research and Markets
Dublin, Nov. 29, 2022 (GLOBE NEWSWIRE) -- The "Flow Cytometry in Oncology and Immunology Market - A Global Market and Regional: Focus on Offering, Technology, End User, Type, Application, and...
The Worldwide Interventional Oncology Industry is Expected to Reach $2.9 Billion by 2028
24 nov. 2022 08h08 HE | Research and Markets
Dublin, Nov. 24, 2022 (GLOBE NEWSWIRE) -- The "Global Interventional Oncology Market Size, Share & Industry Trends Analysis Report By Cancer Type (Liver Cancer, Lung Cancer, Kidney Cancer,...
Global Interventional Oncology Market Analysis Report 2022: A $2.11 Billion Market by 2026 - Forecasts to 2029
23 nov. 2022 06h08 HE | Research and Markets
Dublin, Nov. 23, 2022 (GLOBE NEWSWIRE) -- The "Interventional Oncology Global Market - Forecast to 2026" report has been added to's offering. The Interventional Oncology...
[Latest] Global Respiratory Diagnostics Market Size/Share Worth USD 13.80 Billion by 2030 at an 8.5% CAGR: Custom Market Insights (Testing, Devices, Infection, Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth)
08 nov. 2022 11h58 HE | Custom Market Insights
Sandy, Utah, USA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Respiratory Diagnostic Market Size, Trends and Insights By Product and Services...
Press release Biocartis Group NV: New Idylla™ EGFR Study Shows Reduction of Time-to-Treatment by 48% for Lung Cancer Patients
08 nov. 2022 01h00 HE | Biocartis NV
PRESS RELEASE: 8 November 2022, 07:00 CET New Idylla™ EGFR Study Shows Reduction of Time-to-Treatment by 48% for Lung Cancer PatientsIdylla™ EGFR Mutation Test (CE-IVD) leading to time-to-treatment...
Persbericht Biocartis Group NV: Nieuwe Idylla™ EGFR studie toont reductie van tijd-tot-behandeling met 48% voor longkankerpatiënten
08 nov. 2022 01h00 HE | Biocartis NV
PERSBERICHT: 8 november 2022, 07:00 CET Nieuwe Idylla™ EGFR studie toont reductie van tijd-tot-behandeling met 48% voor longkankerpatiëntenIdylla™ EGFR Mutation Test (CE-IVD) leidt tot een...
Radiotherapy Market to hit USD 11 billion by 2030, says Global Market Insights Inc.
03 nov. 2022 05h10 HE | Global Market Insights Inc.
Selbyville, Delaware, Nov. 03, 2022 (GLOBE NEWSWIRE) -- The radiotherapy market value is anticipated to be over USD 11 billion until the year 2030, according to a new research report by Global...
Noah Medical Presents Data, Showcases the Galaxy System™ at CHEST Annual Meeting
28 oct. 2022 08h00 HE | Noah Medical
SAN CARLOS, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Medical robotics innovator Noah Medical provided physicians attending the American College of Chest Physicians 2022 meeting with a preview of...
SEngines Logo.png
SEngine Precision Medicine Announces New Non-Small Cell Lung Cancer Study at Johns Hopkins University
27 sept. 2022 14h58 HE | SEngine Precision Medicine, Inc.
SEATTLE, Sept. 27, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a Seattle-based precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D...